title: Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma.
abstract: Over the last few decades therapy for multiple myeloma has improved remarkably. In particular, the introduction of novel agents has allowed improved response rates prior to, and after, stem cell transplantation with extension of progression-free survival in high-risk patients. Nevertheless, most patients relapse, leaving multiple myeloma an incurable disease. Despite being the only treatment option that has real curative potential, allogeneic transplantation has not shown its superiority to autologous transplantation due to its high morbidity and mortality rates. This review highlights how novel agents might help to reduce treatment-related mortality and to improve tumor control prior to and post-allogeneic stem cell transplant, which will hopefully result in significantly improved long-term disease control, and maybe a cure following this treatment modality.
authors.affiliation: Department of Internal Medicine II, University of Wurzburg, Klinikstr 6-8, 97070 Wurzburg, Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Kortüm
authors.forename: Stefan
authors.initials: S
authors.lastname: Knop
authors.forename: Hermann
authors.initials: H
authors.lastname: Einsele
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D056747:Immunomodulation; D023421:Models, Animal; D009101:Multiple Myeloma / Q000628:therapy*; D011719:Pyrazines / Q000627:therapeutic use*; D033581:Stem Cell Transplantation; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use*; D014184:Transplantation, Homologous
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib